Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Energy Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B), while Energy Select Sector SPDR Fund trades at $58.51. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| VRTX | XLE | |
|---|---|---|
Market Cap | $121.95B | — |
Sector | Health | — |
52-Week High | $529.59 | $62.57 |
52-Week Low | $366.54 | $42.12 |
Enterprise Value | $116.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
XLE trades at $57.96, up 0.49% today, with a bullish technical signal supported by moving averages but showing overbought RSI readings. The ETF maintains a low 0.08% expense ratio and focuses on S&P 500 energy giants. Recent news highlights XLE's competitive advantages in liquidity and cost structure compared to energy infrastructure ETFs.
Outlook remains positive given elevated oil prices and strong sector earnings growth expectations, though overbought conditions and geopolitical risks warrant caution. The ETF's concentration in major energy companies provides stable exposure to traditional energy sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
